| 000 | 01381 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250514035308.0 | ||
| 264 | 0 | _c20020724 | |
| 008 | 200207s 0 0 eng d | ||
| 022 | _a0028-2685 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTóthová, E | |
| 245 | 0 | 0 |
_aImmune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. _h[electronic resource] |
| 260 |
_bNeoplasma _c2002 |
||
| 300 |
_a91-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aConnective Tissue Diseases _xchemically induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHemolysis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypothyroidism _xchemically induced |
| 650 | 0 | 4 |
_aInterferon Type I _xadverse effects |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xblood |
| 650 | 0 | 4 | _aLeukocyte Count |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPlatelet Count |
| 650 | 0 | 4 |
_aRaynaud Disease _xchemically induced |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 700 | 1 | _aKafková, A | |
| 700 | 1 | _aStecová, N | |
| 700 | 1 | _aFricová, M | |
| 700 | 1 | _aGuman, T | |
| 700 | 1 | _aSvorcová, E | |
| 773 | 0 |
_tNeoplasma _gvol. 49 _gno. 2 _gp. 91-4 |
|
| 999 |
_c11982455 _d11982455 |
||